Lunai Bioworks Inc. SEC filings LNAI
Lunai Bioworks Inc. has 599 filings in SEC EDGAR's recent list, going back to Aug 12, 2011. Its latest annual report, Form 10-K, was filed on Oct 13, 2026 for the period ended Jun 30, 2026. The latest quarterly report (Form 10-Q) was filed on May 15, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (listing notice, officer or director change, regulation fd disclosure, other events). The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 25 | Form 25 | Nov 2, 2026 | — |
| EFFECT | Filing | Oct 26, 2026 | — |
| S-8 POS | Form s-8 pos | Oct 23, 2026 | — |
| POS AM | Form pos am | Oct 23, 2026 | — |
| S-8 POS | Form s-8 pos | Oct 23, 2026 | — |
| 8-K |
Current report
Listing notice, Officer or director change, Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 16, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 15, 2026 | — |
| 10-K | Annual report | Oct 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 9, 2026 | Oct 9, 2026 |
| NT 10-K | Form nt 10-k | Sep 29, 2026 | Jun 30, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 17, 2026 | — |
| 8-K |
Current report
Other events
|
Jun 17, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Other events
|
Jun 16, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Other events
|
May 20, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 13, 2026 | May 8, 2026 |
| 8-K/A |
Amended current report
Listing notice
|
May 11, 2026 | Apr 27, 2026 |
| DEFR14A | Form defr14a | May 1, 2026 | — |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Listing notice, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
May 1, 2026 | Apr 27, 2026 |
| 8-K |
Current report
Other events
|
Apr 28, 2026 | Apr 27, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEFR14A | Form defr14a | Apr 15, 2026 | — |
| DEF 14A | Proxy statement | Apr 13, 2026 | Apr 13, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 2, 2026 | Apr 2, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Mar 30, 2026 | Mar 24, 2026 |
| 8-K |
Current report
Other events
|
Mar 5, 2026 | Feb 27, 2026 |
| 8-K |
Current report
Listing notice
|
Feb 23, 2026 | Feb 17, 2026 |
| 10-Q | Quarterly report | Feb 17, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Feb 12, 2026 | Feb 6, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Dec 9, 2025 | — |
| 424B5 | Prospectus supplement | Dec 3, 2025 | — |
| 8-K |
Current report
Material agreement
|
Dec 3, 2025 | Dec 2, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Nov 28, 2025 | — |
| 8-K |
Current report
Unregistered share sale
|
Nov 25, 2025 | Nov 25, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Nov 12, 2025 | — |
| 8-K |
Current report
Listing notice
|
Nov 6, 2025 | Nov 4, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Nov 3, 2025 | Oct 31, 2025 |
| 8-K |
Current report
Listing notice
|
Oct 30, 2025 | Oct 27, 2025 |
| 8-K |
Current report
Listing notice
|
Oct 16, 2025 | Oct 15, 2025 |
| DEF 14A | Proxy statement | Oct 15, 2025 | Oct 15, 2025 |
| 10-K | Annual report | Sep 29, 2025 | Jun 30, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 26, 2025 | — |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Sep 24, 2025 | Sep 18, 2025 |
| 8-K |
Current report
Impairment, Other events
|
Sep 5, 2025 | Sep 2, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 26, 2025 | Aug 26, 2025 |
| 8-K |
Current report
Listing notice
|
Aug 6, 2025 | Aug 6, 2025 |
| DEF 14A | Proxy statement | Jul 30, 2025 | Jul 30, 2025 |
| 8-K |
Current report
Officer or director change
|
Jul 25, 2025 | Jul 25, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 18, 2025 | Jul 18, 2025 |
| 8-K |
Current report
Listing notice
|
Jul 14, 2025 | Jul 14, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 10, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jul 9, 2025 | Jul 9, 2025 |
| 8-K |
Current report
Officer or director change
|
Jun 5, 2025 | May 30, 2025 |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Listing notice
|
Apr 18, 2025 | Apr 14, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 14, 2025 | — |
| 8-K |
Current report
Unregistered share sale, Other events
|
Apr 10, 2025 | Apr 8, 2025 |
| 4 | Insider transaction | Mar 12, 2025 | Mar 10, 2025 |
| 425 | Form 425 | Mar 6, 2025 | — |
| 8-K |
Current report
Material agreement
|
Mar 6, 2025 | Feb 28, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Feb 28, 2025 | Feb 26, 2025 |
| 4 | Insider transaction | Feb 25, 2025 | Jan 21, 2025 |
| 4 | Insider transaction | Feb 25, 2025 | Jan 21, 2025 |
| 10-Q | Quarterly report | Feb 19, 2025 | Dec 31, 2024 |
| 10-Q/A | Amended quarterly report | Feb 19, 2025 | Sep 30, 2024 |
| 10-K/A | Amended annual report | Feb 19, 2025 | Jun 30, 2024 |
| 10-Q/A | Amended quarterly report | Feb 19, 2025 | Mar 31, 2024 |
| 8-K |
Current report
Restatement
|
Feb 19, 2025 | Feb 18, 2025 |
| NT 10-Q | Form nt 10-q | Feb 18, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 10, 2025 | Feb 4, 2025 |
| 3 | Initial insider ownership | Jan 13, 2025 | Jan 6, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 13, 2025 | Jan 6, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jan 7, 2025 | Jan 1, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 6, 2025 | Dec 30, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 21, 2024 | Nov 15, 2024 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 8, 2024 | Nov 4, 2024 |
| 4 | Insider transaction | Nov 7, 2024 | Nov 4, 2024 |
| EFFECT | Filing | Nov 6, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Nov 6, 2024 | — |
| 4 | Insider transaction | Nov 6, 2024 | Nov 4, 2024 |
| 4 | Insider transaction | Nov 6, 2024 | Nov 4, 2024 |
| 4 | Insider transaction | Nov 6, 2024 | Nov 4, 2024 |
| 3 | Initial insider ownership | Nov 5, 2024 | Oct 14, 2024 |
| CORRESP | Letter to the SEC | Nov 4, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 4, 2024 | — |
| 3 | Initial insider ownership | Oct 31, 2024 | Oct 14, 2024 |
| S-3 | Shelf registration | Oct 30, 2024 | — |
| 8-K/A |
Amended current report
Officer or director change
|
Oct 29, 2024 | Oct 11, 2024 |
| 4 | Insider transaction | Oct 29, 2024 | Oct 14, 2024 |
| 3 | Initial insider ownership | Oct 29, 2024 | Oct 14, 2024 |
| 10-K/A | Amended annual report | Oct 28, 2024 | Jun 30, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Oct 24, 2024 | — |
| 4 | Insider transaction | Oct 24, 2024 | Jul 29, 2024 |
| 3 | Initial insider ownership | Oct 23, 2024 | Oct 14, 2024 |
| 3 | Initial insider ownership | Oct 23, 2024 | Oct 14, 2024 |
| 8-K |
Current report
Listing notice
|
Oct 16, 2024 | Oct 11, 2024 |
| 10-K | Annual report | Oct 10, 2024 | Jun 30, 2024 |
| UPLOAD | Letter from the SEC | Oct 10, 2024 | — |
| NT 10-K | Form nt 10-k | Oct 1, 2024 | Jun 30, 2024 |
| CORRESP | Letter to the SEC | Oct 1, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 25, 2024 | — |
| 8-K |
Current report
Listing notice
|
Sep 17, 2024 | Sep 12, 2024 |
| 8-K |
Current report
Other events
|
Sep 11, 2024 | Sep 11, 2024 |
| 4 | Insider transaction | Aug 27, 2024 | Aug 23, 2024 |
| 10-Q/A | Amended quarterly report | Aug 20, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Restatement, Regulation FD disclosure
|
Aug 19, 2024 | Aug 14, 2024 |
| 4/A | Filing | Aug 16, 2024 | Aug 12, 2024 |
| CORRESP | Letter to the SEC | Aug 16, 2024 | — |
| 4 | Insider transaction | Aug 13, 2024 | Aug 12, 2024 |
| 4 | Insider transaction | Jul 19, 2024 | Jul 17, 2024 |
| 4/A | Primary document | Jul 19, 2024 | Jul 15, 2024 |
| 4/A | Primary document | Jul 19, 2024 | Jul 11, 2024 |
| 4 | Insider transaction | Jul 17, 2024 | Jul 15, 2024 |
| 4 | Insider transaction | Jul 15, 2024 | Jul 9, 2024 |
| UPLOAD | Letter from the SEC | Jul 12, 2024 | — |
| 4 | Insider transaction | Jul 8, 2024 | Jul 3, 2024 |
| 4 | Insider transaction | Jul 3, 2024 | Jul 1, 2024 |
| 8-K |
Current report
Officer or director change
|
Jul 3, 2024 | Jun 27, 2024 |
| 4 | Insider transaction | Jul 3, 2024 | Jun 6, 2024 |
| 4 | Insider transaction | Jul 1, 2024 | Jun 25, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 25, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 25, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 25, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 25, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 25, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 25, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 25, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Jun 24, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jun 21, 2024 | Jun 14, 2024 |
| 4 | Insider transaction | Jun 18, 2024 | Jun 14, 2024 |
| 144 | Notice of proposed sale | Jun 11, 2024 | — |
| 144 | Notice of proposed sale | Jun 6, 2024 | — |
| CORRESP | Letter to the SEC | May 31, 2024 | — |
| 4 | Insider transaction | May 30, 2024 | May 26, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
May 24, 2024 | May 21, 2024 |
| 8-K |
Current report
Other events
|
May 24, 2024 | May 24, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | May 17, 2024 | — |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Other events
|
Apr 30, 2024 | Apr 30, 2024 |
| 8-K |
Current report
Other events
|
Apr 25, 2024 | Apr 24, 2024 |
| 8-K/A | Amended current report | Apr 24, 2024 | Feb 9, 2024 |
| UPLOAD | Letter from the SEC | Apr 22, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Apr 8, 2024 | — |
| 4 | Insider transaction | Mar 19, 2024 | Mar 6, 2024 |
| 4 | Insider transaction | Mar 13, 2024 | Mar 11, 2024 |
| 3 | Initial insider ownership | Mar 13, 2024 | Mar 11, 2024 |
| 8-K |
Current report
Officer or director change
|
Mar 13, 2024 | Mar 11, 2024 |
| CORRESP | Letter to the SEC | Mar 11, 2024 | — |
| 8-K |
Current report
Agreement ended
|
Mar 7, 2024 | Mar 1, 2024 |
| 8-K |
Current report
Officer or director change
|
Mar 5, 2024 | Feb 28, 2024 |
| 4 | Insider transaction | Feb 28, 2024 | Dec 27, 2023 |
| 3 | Initial insider ownership | Feb 23, 2024 | Feb 13, 2022 |
| D | Filing | Feb 23, 2024 | — |
| 4 | Insider transaction | Feb 22, 2024 | Feb 20, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 22, 2024 | — |
| 4 | Insider transaction | Feb 20, 2024 | Aug 22, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Feb 16, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Feb 16, 2024 | — |
| 4 | Insider transaction | Feb 16, 2024 | Feb 13, 2024 |
| 3/A | Filing | Feb 16, 2024 | Jul 22, 2022 |
| 4 | Insider transaction | Feb 16, 2024 | Feb 13, 2024 |
| 4 | Insider transaction | Feb 16, 2024 | Feb 13, 2024 |
| 8-K |
Current report
Other events
|
Feb 16, 2024 | Feb 16, 2024 |
| 4 | Insider transaction | Feb 15, 2024 | Feb 13, 2024 |
| 10-Q | Quarterly report | Feb 14, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Feb 14, 2024 | Feb 9, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Feb 7, 2024 | Feb 1, 2024 |
| 4 | Insider transaction | Feb 2, 2024 | Dec 27, 2023 |
| UPLOAD | Letter from the SEC | Jan 30, 2024 | — |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jan 25, 2024 | Jan 25, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Jan 24, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jan 24, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jan 24, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jan 24, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jan 24, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jan 24, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jan 24, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jan 24, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jan 24, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Jan 24, 2024 | — |
| DEFA14A | Additional proxy material | Jan 16, 2024 | — |
| 8-K |
Current report
Other events
|
Jan 16, 2024 | Jan 16, 2024 |
| 8-K |
Current report
Other events
|
Jan 16, 2024 | Jan 16, 2024 |
| DEFA14A | Additional proxy material | Jan 16, 2024 | — |
| DEFM14A | Form defm14a | Jan 3, 2024 | — |
| PREM14A | Filing | Dec 22, 2023 | Dec 22, 2023 |
| DEFA14A | Additional proxy material | Dec 22, 2023 | — |
| DEFA14A | Additional proxy material | Dec 11, 2023 | — |
| DEFA14A | Additional proxy material | Dec 7, 2023 | — |
| DEFA14A | Additional proxy material | Dec 1, 2023 | — |
| DEFA14A | Additional proxy material | Dec 1, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 1, 2023 | Dec 1, 2023 |
| DEFA14A | Additional proxy material | Nov 22, 2023 | — |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| 4 | Insider transaction | Nov 14, 2023 | Oct 23, 2023 |
| 3 | Initial insider ownership | Nov 14, 2023 | Oct 11, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Nov 3, 2023 | — |
| DEFA14A | Additional proxy material | Nov 2, 2023 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LNAI (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Suite 906 Los Angeles, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1527728
- Former names
- RENOVARO INC. (until Aug 26, 2025); RENOVARO BIOSCIENCES INC. (until Feb 7, 2024); Enochian Biosciences Inc (until Aug 1, 2023); DanDrit Biotech USA, Inc. (until Feb 23, 2018); Putnam Hills Corp. (until Feb 11, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.